Rejuveron increases to near-majority stake in Endogena to progress treatments for degenerative diseases of the eye.
Rejuveron funds $29 million for degenerative eye disease
Posted in biotech/medical
Posted in biotech/medical
Rejuveron increases to near-majority stake in Endogena to progress treatments for degenerative diseases of the eye.